AstraZeneca signs deal with Torrent to tap into emerging markets
This article was originally published in Scrip
AstraZeneca is following other large pharmaceutical companies such as Pfizer and GlaxoSmithKline into emerging markets with a basket of branded generic products from India's Torrent Pharmaceuticals.
You may also be interested in...
Eris Lifesciences has acquired a Novartis trademark for vildagliptin, a DPP-4 inhibitor that has been the subject of a torrent of alleged infringement-related legal action in India. Pricing for the acquired brand will be interesting to watch from now on as a patent on vildagliptin is set to expire soon.
Cipla’s global chief operating officer is leaving the company to pursue new interests, amid a spate of top-level exits that have marked the pharma sector in India in 2019.